Please assess the completion status of the following clinical trial:

Trial Title: Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed melanoma~  * Metastatic disease~    * Brain metastases, skin metastases, or soft tissue metastases of the head and neck or the extremities~ * Accessible lesion(s) for boron neutron capture therapy (BNCT)~ * No clear progression of disease at other sites than the ones intended for treatment with surgery and/or BNCT~* Measurable disease by MRI within the past 4 weeks~  * Lesion(s) ≥ 10 mm in diameter~* Indication for palliative radiotherapy that is intended to be delivered as BNCT~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~Hepatic~* Bilirubin ≤ 2.5 times upper limit of normal (ULN)\*~* Transaminases ≤ 2.5 times ULN\*~* Alkaline phosphatase ≤ 2.5 times ULN\* NOTE: \*Unless due to reversible reaction to antiseizure medication~Renal~* Creatinine ≤ 2.5 times ULN~* Blood urea nitrogen ≤ 2.5 times ULN~Cardiovascular~* No congestive heart failure~* No newly diagnosed or unstable angina pectoris~* No uncontrolled arrhythmias~* No uncontrolled conduction defects~* No recent coronary artery disease~* No other severe heart disease~Pulmonary~* No severe pulmonary disease, including severe obstructive or restrictive lung disease~Other~* No history of phenylketonuria~* No severe gastrointestinal disease~* No active peptic ulcer disease~* No uncontrolled endocrine disease~* No pre-existing serious mental or organic brain disease (e.g., epilepsy)~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Able to travel to the Netherlands via public transportation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunologic or biologic therapy~* No concurrent colony-stimulating factors (e.g., epoetin alfa or filgrastim \[G-CSF\])~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy~Radiotherapy~* No prior radiotherapy to site(s) proposed for study treatment~* No other concurrent radiotherapy~Surgery~* See Disease Characteristics~Other~* Recovered from all prior anti-tumor therapy (excluding alopecia and sensitive peripheral neuropathy ≤ grade 2)~* No other concurrent anticancer therapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).